Arq Announces $15 Million PIPE Transaction Entered Into $15 million PIPE at $7.00 per share, reflecting a roughly 3% discount to yesterday's close Transaction resulted from unsolicited offer from new, accredited institutional investor Bolsters long-term growth strategy, provides additional third-party validation of strategy and prospects GREENWOOD VILLAGE, Colo., May 16, 2024 (GLOBE NEWSWIRE) -- Arq, Inc. (NASDAQ: ARQ) (the "Company" or "Arq"), a producer of activated carbon and other environmentally efficient carbon products for use in purification and sustainable materials, today an...
Two Directors at Harte-Hanks Inc bought/maiden bought 11,175 shares at between 7.093USD and 7.200USD. The significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direc...
A director at Williams Companies Inc sold 38,200 shares at 39.610USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 Conference MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abstracts on primary biliary cholangitis (PBC) will be presented at Digestive Disease Week® (DDW) 2024. The conference will be held from May 18-21 in Washington, D.C. “We are pleased to participate i...
BioXcel Therapeutics Reports First Quarter 2024 Financial Results Advancing TRANQUILITY and SERENITY program plans for two pivotal Phase 3 trials to expand BXCL501 market potential in acute treatment of agitation Strengthened intellectual property portfolio for BXCL501 with grant of two new patents, in Japan and the U.S. Completed $25 million registered direct offering Conference call set for 8:00 a.m. ET today NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop tran...
Arq Reports First Quarter 2024 Results Delivered materially improved YoY results in Q1 from PAC margin enhancement Achieved strategic milestone with first GAC contract for 20% of capacity at attractive pricing Red River expansion remains on schedule for first production in Q4 2024; expected payback of 3 years or less GREENWOOD VILLAGE, Colo., May 08, 2024 (GLOBE NEWSWIRE) -- Arq, Inc. (NASDAQ: ARQ) (the "Company" or "Arq"), a producer of activated carbon and other environmentally efficient carbon products for use in purification and sustainable materials, today announced its financial...
Arq Announces First Supply Contract for its Strategic Granular Activated Carbon (GAC) Facility Achieved critical strategic milestone with the execution of its first supply contract for Granular Activated Carbon ("GAC") product with a new customer Agreement reflects 5 million pounds/year of GAC with delivery commencing in Q1 2025; Arq’s Red River GAC plant is on target to complete commissioning in Q4 2024 Encouraging ongoing discussions with additional potential customers for further GAC contracts; Arq expects additional near-term announcements GREENWOOD VILLAGE, Colo., May 08, 202...
Fossil Group, Inc. Reports First Quarter 2024 Financial Results Maintains Full Year 2024 Outlook RICHARDSON, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Fossil Group, Inc. (NASDAQ: FOSL) today announced financial results for the first quarter ended March 30, 2024. First Quarter Summary First quarter worldwide net sales decreased to $255 million, down 22% on a reported basis and 21% in constant currency, reflecting five points of impact related to the Company’s strategic actions to exit the smartwatch category and optimize its retail store portfolio.Gross margins expanded 300 basis points t...
eXp World Holdings Reports Q1 2024 Results BELLINGHAM, Wash., May 01, 2024 (GLOBE NEWSWIRE) -- eXp World Holdings, Inc. (Nasdaq: EXPI), or the “Company”, the holding company for eXp Realty®, FrameVR.io and SUCCESS® Enterprises, today announced financial results for the first quarter ended March 31, 2024. “During the first quarter, our agents closed over $37 billion of transactions, a 12% year-over-year increase, underscoring eXp’s unparalleled scale in the cloud brokerage market we pioneered,” said Glenn Sanford, eXp World Holdings Founder, Chairman and CEO. “We continue to provid...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024 NEW HAVEN, Conn., April 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets. BioXcel Therapeutics’ management team will also host a conference call and webcast at 8:00 AM ET that day to discuss the Company’s...
Fossil Group, Inc. Announces Date for First Quarter 2024 Earnings Release and Conference Call RICHARDSON, Texas, April 24, 2024 (GLOBE NEWSWIRE) -- Fossil Group, Inc. (NASDAQ: FOSL) announced today that it will report first quarter 2024 financial results after market close on Wednesday, May 8, 2024, followed by a conference call to discuss the results at 5:00 p.m. ET the same day. The call can be accessed live on the Company’s investor relations website at /investors and will also be archived for replay. About Fossil Group, Inc. Fossil Group, Inc. is a global design, marketing, distribu...
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University’s Lombardi Comprehensive Cancer Center NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transforma...
Arq to Host First Quarter 2024 Conference Call on May 9, 2024 GREENWOOD VILLAGE, Colo., April 24, 2024 (GLOBE NEWSWIRE) -- Arq, Inc. (NASDAQ: ARQ) (the "Company" or "Arq"), a producer of activated carbon and other environmentally efficient carbon products for use in purification and sustainable materials, today announced the Company expects to release its first quarter 2024 financial results and file its Quarterly Report on Form 10-Q for the period ended March 31, 2024 after market close on Wednesday, May 8, 2024. A conference call to discuss the Company's financial performance is schedul...
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential Company plans to initiate SERENITY At-Home pivotal Phase 3 safety trial with 120 mcg dose following recent meeting with FDA No FDA-approved therapies for acute treatment of agitation associated with bipolar disorders or schizophrenia in the home setting NEW HAVEN, Conn., April 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-...
eXp World Holdings to Announce First Quarter 2024 Results on May 1, 2024 Management to discuss first quarter 2024 results and host investor Q&A at virtual event BELLINGHAM, Wash., April 17, 2024 (GLOBE NEWSWIRE) -- eXp World Holdings, Inc. (Nasdaq: EXPI), the holding company for eXp Realty®, Virbela and SUCCESS® Enterprises, today announced it expects to report its first quarter 2024 financial results on Wednesday, May 1, 2024. The Company will hold a virtual fireside chat and investor Q&A on Wednesday, May 1, 2024 at 2 p.m. PT / 5 p.m. ET hosted by, Glenn Sanford, Founder, Chairman a...
Arq Applauds EPA's First-Ever Definitive PFAS Regulations On April 10, 2024, the EPA issued its first-ever national, legally enforceable PFAS regulations, confirming stricter rules reducing permissible PFAS levels by more than 90% Changes are focused on reducing PFAS contamination in U.S. drinking water, protecting public health and improving environmental integrity Regulations are expected to drive even stronger near and long-term demand for Arq's solutions, including its unique waste-derived Granular Activated Carbon ("GAC") GREENWOOD VILLAGE, Colo., April 11,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.